agilon health stock has delivered a very large year to date gain, yet the current valuation checks still lean cheap. This sets up a clear question of whether the recent enthusiasm has run ahead of fundamentals or if the market is only starting to reprice the business.

• Year to date, agilon health is up a very large 563.5%, which puts extra focus on whether the current price leaves enough room for mistakes.
• Recent analyst upgrades tied to an improved outlook for value based care and margin expansion can support higher earnings expectations. At the same time, any setback in delivering those margins or changes in Medicare Advantage dynamics may quickly test the current valuation.
• agilon health scores highly on Simply Wall St's broader valuation checks, screening as undervalued in 5 of 6 areas. This suggests the stock still looks inexpensive across several common metrics despite the sharp move.

The issue now is whether agilon health's recent rerating has already absorbed most of that apparent undervaluation or if there is still a margin of safety at current levels.

Is agilon health a Bargain on Sales?

The P/S multiple suits agilon health because revenue is currently a more consistent reference point than earnings. The stock trades on a P/S of around 0.3x, which is well below both the Healthcare industry average of about 1.5x and a peer group average of roughly 2.4x. That is a wide gap for a business that investors are watching closely within value based care.

On Simply Wall St's more tailored fair ratio, which adjusts for agilon health's size, risk profile and sector, the stock would screen closer to 0.5x sales. The current 0.3x level sits materially under that. This is why it flags as undervalued on this measure. Despite recent analyst upgrades and a strong share price move, the valuation on sales still implies a discount versus what the model suggests and what similar companies trade on.

On the P/S multiple, agilon health stock appears undervalued relative to both its tailored fair ratio and sector benchmarks.

The agilon health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where agilon health's valuation puzzle leaves off by explaining which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today based on those assumptions. Each Narrative links a specific fair value estimate to a clear story about agilon health's potential catalysts and risks, giving you a framework to track which version of events is gradually taking shape on the Community page.

One of the top community narratives on agilon health: 408% overvalued

"Operational challenges, missed internal targets, and unfavorable cost trends threaten agilon health's profitability, with risks compounded by contract uncertainties and intensifying competition in value-based care."

Do you think there's more to the story for agilon health? Head over to our Community to see what others are saying!

The Bottom Line

agilon health still screens as undervalued on sales based metrics, even after a very large year to date move. This suggests the market has not fully closed the gap implied by its current multiples. The tension for investors is whether that discount reflects genuine mispricing or a reasonable cushion for execution risk, especially around margins and Medicare Advantage exposure. The core question from here is whether agilon health can deliver the margin and profitability path that would justify even a partial re rating, or whether operational and reimbursement pressures turn today’s apparent discount into a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.